Cargando…
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
BACKGROUND: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA). In 2013, the decision was made to transfer the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH), to align the p...
Autores principales: | Rocchi, Angela, Chabot, Isabelle, Glennie, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/ https://www.ncbi.nlm.nih.gov/pubmed/26082654 http://dx.doi.org/10.2147/CEOR.S82549 |
Ejemplares similares
-
Oncology drug health technology assessment recommendations: Canadian versus UK experiences
por: Chabot, Isabelle, et al.
Publicado: (2014) -
Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs
por: Saluja, Ronak, et al.
Publicado: (2021) -
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
por: Masucci, Lisa, et al.
Publicado: (2017) -
Integrative practices of Canadian oncology health professionals
por: Brazier, A.S.A., et al.
Publicado: (2008) -
Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study
por: Lexchin, Joel
Publicado: (2019)